21394-91-2Relevant articles and documents
Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators
Rodrigues, Tiago,Lin, Yen-Chu,Hartenfeller, Markus,Renner, Steffen,Lim, Yi Fan,Schneider, Gisbert
, p. 7478 - 7481 (2015)
Using computational bioactivity prediction models we identified phosphodiesterase 3B (PDE3B) and cathepsin L as macromolecular targets of de novo designed compounds. By disclosing the most potent cathepsin L activator known to date, small molecule repurposing by target panel prediction represents a feasible route towards innovative leads for chemical biology and molecular medicine. This journal is
Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof
-
Paragraph 2086; 2088-2090, (2020/08/28)
The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.
Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
-
, (2008/06/13)
Substituted 6-phenyl-3(2H)-pyridazinone compounds are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are dehydrogenated to the desired product. The intermediate 6-phenyl-4,5-dihydro-3(2H)-pyridazinones are themselves useful as cardiotonic agents.